Sana Biotechnology (Nasdaq:SANA) - Aandelenkoers, Nieuws & Analyse

SANA Overzicht aandelen

Sana Biotechnology, Inc., een biotechnologiebedrijf, richt zich op het gebruik van gemanipuleerde cellen als medicijnen.

Over het bedrijf

SANA fundamentele analyse
Sneeuwvlok Score
Waardering	1/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	5/6
Dividenden	0/6

Beloningen

Risicoanalyse

De winst zal naar verwachting de komende drie jaar met gemiddeld 3.8% per jaar dalen.

Heeft een omzet van minder dan 1 miljoen USD ( $0 )

Aandeelhouders zijn het afgelopen jaar verwaterd

Heeft minder dan 1 jaar cash runway

+ 1 meer risico

Sana Biotechnology, Inc. Concurrenten

89bio

NasdaqGM:ETNB

US$824.0m

Silence Therapeutics

NasdaqGM:SLN

US$809.6m

Prothena

NasdaqGS:PRTA

US$914.3m

MiMedx Group

NasdaqCM:MDXG

US$1.0b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Sana Biotechnology
Historische aandelenkoersen
Huidige aandelenkoers	US$3.50
52 Week Hoogtepunt	US$12.00
52 Week Laag	US$3.06
Bèta	1.42
11 maand verandering	-19.72%
3 maanden verandering	-30.56%
1 Jaar Verandering	-0.85%
33 jaar verandering	-84.61%
5 jaar verandering	n/a
Verandering sinds IPO	-90.03%

Recent nieuws en updates

Sana Biotechnology: Early-Stage Biotech With Promising Allogeneic CAR-T Pipeline

Jul 14

We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Jul 12

Recent updates

Sana Biotechnology: Early-Stage Biotech With Promising Allogeneic CAR-T Pipeline

Jul 14

We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Jul 12

Sana Biotechnology: Now In Overbought Territory

Mar 17

Sana Biotechnology's One-And-Done Solution For Diabetes Impresses In NHP Model (Rating Upgrade)

Jan 11

Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

Dec 30

Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

Sep 14

Will Sana Biotechnology (NASDAQ:SANA) Spend Its Cash Wisely?

May 26

We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Dec 19

Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

Sep 03

Sana Biotechnology A Buy For Potential Cancer Therapies

Jun 27

Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

May 16

Rendement voor aandeelhouders

	SANA	US Biotechs	US Markt
7D	-6.9%	-1.3%	-1.6%
1Y	-0.8%	19.1%	30.1%

Rendement versus industrie: SANA presteerde slechter dan de US Biotechs -sector, die het afgelopen jaar een rendement van 19.1 % opleverde.

Rendement versus markt: SANA presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 30.1 % opleverde.

Prijsvolatiliteit

Is SANA's price volatile compared to industry and market?
SANA volatility
SANA Average Weekly Movement	9.3%
Biotechs Industry Average Movement	9.6%
Market Average Movement	6.1%
10% most volatile stocks in US Market	15.1%
10% least volatile stocks in US Market	3.0%

Stabiele aandelenkoers: SANA heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 9% ) van SANA is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2018	328	Steve Harr	www.sana.com

Sana Biotechnology, Inc., een biotechnologiebedrijf, richt zich op het gebruik van gemanipuleerde cellen als medicijnen. Het ontwikkelt ex vivo en in vivo celtechnologieplatforms voor verschillende therapeutische gebieden met onbeantwoorde behandelingsbehoeften, waaronder oncologie, diabetes, aandoeningen van het centrale zenuwstelsel, B-cel-gemedieerde auto-immuunziekten en andere. De productkandidaten van het bedrijf omvatten SC291, dat wordt gebruikt als allogene celtherapie voor hematologische maligniteiten; ARDENT voor een potentiële behandeling van non-Hodgkin lymfoom en chronische lymfoblastische leukemie; GLEAM, voor de behandeling van meerdere autoimmuunziekten waarbij sprake is van de productie van autoimmuunantilichamen, waaronder lupusnefritis, lupus extrarenalis, antineutrofiele cytoplasmatische antilichamen -geassocieerde vasculitis, en andere.

Sana Biotechnology, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Sana Biotechnology zich tot de beurswaarde?
SANA fundamentele statistieken
Marktkapitalisatie	US$778.63m
Inkomsten(TTM)	-US$244.90m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-3.2x

Koers/Winstverhouding

Is SANA overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
SANA resultatenrekening (TTM)
Inkomsten	US$0
Kosten van inkomsten	US$0
Brutowinst	US$0
Overige uitgaven	US$244.90m
Inkomsten	-US$244.90m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-1.10
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde SANA op de lange termijn?

Bekijk historische prestaties en vergelijking

SANA Overzicht aandelen

Beloningen

Risicoanalyse

Sana Biotechnology, Inc. Concurrenten

NasdaqGM:ETNB

US$824.0m

NasdaqGM:SLN

US$809.6m

NasdaqGS:PRTA

US$914.3m

NasdaqCM:MDXG

US$1.0b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Vice Chairman notifies of intention to sell stock

Sana Biotechnology, Inc. Announces Resignation of Nathan Hardy as Executive Vice President, Effective October 4, 2024

Sana Biotechnology, Inc. Announces the Appointment of Dhaval Patel as Executive Vice President and Chief Scientific Officer

New minor risk - Financial position

Sana Biotechnology: Early-Stage Biotech With Promising Allogeneic CAR-T Pipeline

We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Recent updates

Vice Chairman notifies of intention to sell stock

Sana Biotechnology, Inc. Announces Resignation of Nathan Hardy as Executive Vice President, Effective October 4, 2024

Sana Biotechnology, Inc. Announces the Appointment of Dhaval Patel as Executive Vice President and Chief Scientific Officer

New minor risk - Financial position

Sana Biotechnology: Early-Stage Biotech With Promising Allogeneic CAR-T Pipeline

We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Sana Biotechnology, Inc.(NasdaqGS:SANA) dropped from Russell 2000 Value Index

Price target increased by 9.3% to US$12.20

New major risk - Revenue and earnings growth

Sana Biotechnology, Inc. Highlights Publication in Nature Biotechnology of Novel in Vivo Preclinical Data Showing the Potential for Pluripotent Stem Cell-Derived Human Glial Progenitor Cell Transplantation as A Treatment for Huntington's Disease and Other Glial-Based Neurodegenerative Conditions

Sana Biotechnology, Inc., Annual General Meeting, Jun 06, 2024

Sana Biotechnology: Now In Overbought Territory

Independent Director recently sold US$236k worth of stock

Price target increased by 17% to US$10.50

Sana Biotechnology, Inc. Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in Diabetic NHP

Sana Biotechnology, Inc. has completed a Follow-on Equity Offering in the amount of $164.998727 million.

Sana Biotechnology, Inc. has completed a Follow-on Equity Offering in the amount of $164.998727 million.

Sana Biotechnology's One-And-Done Solution For Diabetes Impresses In NHP Model (Rating Upgrade)

Sana Biotechnology, Inc. Announces FDA Clearance of Investigational New Drug Application for SC262

Insufficient new directors

Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

Executive VP & Chief Business Officer notifies of intention to sell stock

Sana Biotechnology, Inc. Highlights Preclinical Data Supporting Tumor Control and Immune Evasion Capabilities of Hypoimmune-Modified Allogeneic Car T Cells in Presentations At the American Society of Hematology Annual Meeting

Sana Biotechnology Publishes Early Clinical Data Showing That Sc291, A Cd19-Directed Allogeneic Car T Therapy, Evades Immune Detection in Presence of Intact Immune System

Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for Sc291, A Hypoimmune-Modified, Cd19-Directed Allogeneic Car T Therapy, for Patients with Lupus Nephritis, Extrarenal Lupus, and Anca-Associated Vasculitis

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Sana Biotechnology, Inc. Announces Increased Focus on Hypoimmune-Related Pipeline with the Potential to Deliver Clinical Proof of Concept Data from Four Programs in 2023 and 2024 with A 2024 Operating Burn Under $200M

Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

Price target increased by 8.6% to US$9.50

New major risk - Revenue and earnings growth

Will Sana Biotechnology (NASDAQ:SANA) Spend Its Cash Wisely?

Price target decreased by 10% to US$8.75

Sana Biotechnology, Inc. Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-targeted Allogeneic CAR T Therapy for Patients with B-Cell Malignancies

We're Keeping An Eye On Sana Biotechnology's (NASDAQ:SANA) Cash Burn Rate

Price target decreased to US$9.75

High number of new directors

Price target decreased to US$11.75

Here's Why We're Watching Sana Biotechnology's (NASDAQ:SANA) Cash Burn Situation

High number of new directors

Sana Biotechnology A Buy For Potential Cancer Therapies

Sana Biotechnology, Inc.(NasdaqGS:SANA) dropped from Russell 2500 Growth Index

Sana Biotechnology, Inc. Presents Data at ISSCR 2022 Annual Meeting Showing Survival of Transplanted Hypoimmune iPSC-Derived Differentiated Cell Types Without Immunosuppression in Non-Human Primates

Sana Biotechnology, Inc. Plan to Relocate Manufacturing to Bothell

Sana Biotechnology Announces Plan to Relocate Manufacturing to Bothell, Washington

Price target decreased to US$12.50

Is Sana Biotechnology (NASDAQ:SANA) In A Good Position To Deliver On Growth Plans?

Sana Biotechnology, Inc. to Present Data from Multiple Preclinical Studies at the American Society of Gene and Cell Therapy 25th Annual Meeting

Price target decreased to US$18.00

High number of new directors

Independent Director recently bought US$204k worth of stock

Price target decreased to US$23.67

Sana Biotechnology: Exciting Preclinical Science

Is Sana Biotechnology, Inc. (NASDAQ:SANA) Trading At A 38% Discount?

Executive VP notifies of intention to sell stock

Independent Director Geoffrey von Maltzahn has left the company

Senior VP & Chief Business Officer notifies of intention to sell stock

Sana Biotechnology: Hypoimmune Cell Therapies

Sana Biotechnology, Inc.(NasdaqGS:SANA) dropped from Russell 1000 Value Index